SCHEMBL1624967

SCHEMBL1624967

CN1CCN(C(=O)C2CCN(c3ccc(Cl)c(-c4nc5cc(F)ccc5[nH]4)c3)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 4/20 0.44
BRD4 O60885 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PDGFRB P09619 2/20 0.42
FGFR1 P11362 2/20 0.42
KDR P35968 2/20 0.42
TP53 P04637 1/20 0.42
HRH4 Q9H3N8 2/20 0.41
VCP P55072 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TNKS O95271 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1625515 0.92 KCNH2 (0.52) KCNH2LMNAMAPTBRD4SMN1; SMN2
SCHEMBL1625942 0.90 MAPT (0.52) KCNH2LMNAMAPTBRD4SMN1; SMN2
SCHEMBL1623740 0.90 DGAT2 (0.46) BRD4
SCHEMBL1284134 0.90 NOTUM (0.49) LMNAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL1625946 0.89 LMNA (0.42) KCNH2LMNAMAPTSMN1; SMN2TP53
SCHEMBL3508339 0.89 LMNA (0.59) KCNH2LMNAMAPTBRD4PDGFRB
SCHEMBL1625272 0.88 MAPT (0.50) KCNH2LMNAMAPTBRD4SMN1; SMN2
SCHEMBL1625215 0.88 LMNA (0.51) KCNH2LMNAMAPTBRD4SMN1; SMN2
SCHEMBL1624994 0.87 FGFR1 (0.47) LMNAMAPTFGFR1KDRTP53
SCHEMBL1625881 0.87 KCNH2 (0.47) KCNH2LMNAMAPTBRD4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO KCNH2 4706/4885LMNA 4481/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.